Johnson & Johnson Archives -

J&J must ditch 60m COVID jabs made at US plant, but 10m are okay, says FDA

https://pharmaphorum.com/news/jj-must-ditch-60m-covid-jabs-made-at-us-plant-but-10m-are-okay-says-fda/

Pharmaceutical Manufacturing and Packaging Congress 2021

https://pharmaphorum.com/events/pharmaceutical-manufacturing-and-packaging-congress-2021/

J&J backs out of $1.6bn blood cancer antibody alliance with Argenx

https://pharmaphorum.com/news/jj-backs-out-of-1-6bn-blood-cancer-antibody-alliance-with-argenx/

ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence data

https://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/

BIO-Europe Spring Digital: Nerida Scott, J&J’s EMEA Innovation Head

https://pharmaphorum.com/video/nerida-scott-interview-with-jjs-emea-innovation-head/

Janssen COVID jab cleared in UK as fears of third wave mount

https://pharmaphorum.com/news/janssen-covid-jab-cleared-in-uk-as-fears-of-third-wave-mount/

FDA sets November review date for J&J’s multiple myeloma CAR-T cilta-cel

https://pharmaphorum.com/news/fda-sets-november-review-date-for-jjs-multiple-myeloma-car-t-cilta-cel/

Belgium halts dosing of J&J COVID vaccine in under 41s after death

https://pharmaphorum.com/news/belgium-halts-dosing-of-jj-covid-vaccine-in-under-41s-after-death/

Straight after its first cancer bispecific OK, J&J highlights two more at ASCO

https://pharmaphorum.com/news/straight-after-its-first-cancer-bispecific-ok-jj-highlights-two-more-at-asco/

Search